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Introduction
• Lynch Syndrome (LS) is a cancer
susceptibility syndrome
• Formerly known as Hereditary NonPolyposis Colorectal Cancer Syndrome
(HNPCC)
• Autosomal dominant inherited trait
• High penetrance, due to defects in repairing
base mismatches during DNA replication
(Shulman, 2015, p. 33)
• Significantly more susceptible to colorectal
(CRC), endometrial and many other types of
cancer
• 50% chance of inheritance if one parent
affected
• Four genes become mutated, called
mismatch repair (MMR) genes, these
mutations can lead to replication of cancer
causing cells (Mange et al., 2015, p. 421-2)
• New recommendations within the last five
years include screening for LS in all newly
diagnosed CRCs
• Universal screening reduces mortality and
increases surveillance for those with a
familial history of LS (Vindigni & Kaz, 2016,
p. 975)
• CRC incidence has declined in the Unites
States due to increased screening methods
including occult blood tests and
colonoscopies (Wanebo et al., 2012, p. 822)
• CRC is the third most common cancer
worldwide, and second leading cause of
cancer-related death
• LS accounts for 1-3% of these tumors
(Moreira et al., 2012, p. 1555)

Topic Selection
• Advancing cancer technology is
relevant to advanced practice nursing
• Knowledge of current
recommendations is essential to
evidence based practice

Pathophysiology
• Mismatch repair mutation
(MMR) occurs in one of the
following genes: MLH1, MSH2,
MSH6, PMS2
• Mismatch repair corrects DNA
replication mistakes
• Loss of function in the MMR
gene means two hits must
occur, one hit to each allele
• Germline mutations are
transmitted to offspring
• Mutation leads to loss of
original function or expression,
which leads to pathogenesis
(Liu et al., 2016, p. 417-18)
• Errors accumulate during DNA
replication easily in repetitive
sequences of DNA called
microsatellites, this is called
microsatellite instability (MSI)
or loss of MMR protein
expression, which defines LS
(Moreira et al., 2012, p. 1556)
• See difference in mutation type
for LS compared to
spontaneous CRC (Sinicrope,
2010, figure 1)

Figure 1. Lynch Syndrome compared to sporadic colorectal cancer,
differences in mutations illustrated, both leading to cancer

Significance of
Pathophysiology
• Pathology plays a major impact in
how to screen individuals and
families
• Updated recommendations
• Old screening tools (Amsterdam I,
Amsterdam II, and revised
Bethesda guideline) determined if
an individual was at high risk for
LS based on personal and family
history
• Still sometimes used but these
tools can miss patients who
should be tested for LS
• Tumor-based screening protocols
better identify those with LS
according to the CDC (Mange et
al., 2015, p. 422)
• Experts recommend that every
person newly diagnosed with CRC
or endometrial cancer be
screened for LS, this is referred to
as universal screening (Vindigni
& Kaz, 2016, p. 971)
• The Lynch Syndrome Screening
Network (LSSN) created in 2011
promotes universal screening,
website is
http://www.lynchscreening.net
(Mange et al., 2015, p. 421 & 424)
• Figure 2 is a sample algorithm for
universal CRC screening (Vindigni
& Kaz, 2016, figure 1)
• Testing is by
immunohistochemistry (IHC),
which determines whether or not
the four types of repair genes are
present on a tissue sample
(Shulman, 2015, p. 35)
• The other form of testing looks
for microsatellite instability
which are errors in repetitive
DNA sequences (see Figure 3)
• Testing for both IHC and MSI
reduces the likelihood of missing
a diagnosis of LS
• If LS is positive,
recommendations also involve
screening family members
(Vindigni & Kaz, 2016, p. 970)

Significance to Nursing

Figure 3. http://kintalk.org/whats-lynchsyndrome/diagnosing-lynch-syndrome/

Signs and Symptoms
• Treatment depends on cancer location and metastasis
• Liver metastasis results in significant mortality
(Wanebo et al., 2012, p. 834)
• Individuals develop cancer at an earlier age than
sporadic cancers, average age of onset is 45 (Liu,
Thompson, Ward, Hesson, & Sloane, 2016, p. 417)
• Colorectal and endometrial cancer are the two main
cancers seen, but LS also increases risk for ovarian,
stomach, small intestine, hepatobiliary tract, upper
urinary tract, brain, and skin cancers (Ten Broeke et
al., 2015, p. 325)
• Signs and symptoms vary according to the type of
cancer
• Cancer risks:
LS LS +
LS LS +

4-5% CRC
20-60% CRC
2-3% Endometrial CA
20-60% Endometrial CA

Figure 2. Universal testing algorithm for
colorectal cancer

• Important to educate and guide
patients
• Emotional burdens are associated
with hereditary cancer and
associated knowledge
• Psychological effects have focused
on family genetic testing and
screening related to Huntington’s
disease and the BRCA1/2 gene
associated with breast cancer
• Most studies focus on immediate
family and not extended family
• Cancer distress, cancer worry, and
depression all need to be further
researched when considering
familial genetic testing (Eliezer,
Hadley, & Koehly, 2014, p. 1293)
• Practice with empathy and
awareness to empower patients
and decide what to do with the
knowledge they are able to
uncover through genetic testing
• Preventative medicine and
primary prevention is far more
effective than tertiary prevention
interventions, and the information
behind LS allows more
opportunities to prevent cancer
rather than treat

Conclusions
• Genetic advances will continue to
evolve and screening
recommendations for individuals
and families will continually
change
• Knowledge is power: current
knowledge must be used in a way
to benefit the general population
• Increasing awareness is essential,
providers must be informed about
new screening guidelines
• LS poses a significant risk for
developing cancer but screening
tools are causing decline in
colorectal cancer mortality
(Wanebo et al., 2012, p. 822)
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